Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

A New Living Cancer Drug for Treating Lymphoid Tumors: CAR-NK

A New Living Cancer Drug for Treating Lymphoid Tumors: CAR-NK

Chimeric antigen receptor (CAR) T-cell therapies, in which immune cells are modified to fight tumor cells, expanded, and administered to a patient, have been among oncology's most important developments over the last 5 years. However, preparing and administering this cellular immunotherapy presents major challenges and costs. A study reporting that using NK cells instead of T cells could achieve the same effect with far fewer adverse effects has therefore attracted considerable interest. New England Journal of Medicinepublished a phase I / II clinical trial in which Liu and colleagues studied the cell-surface receptor CD19 in patients with positive lymphoid tumors and anti-CD19 chimeric antigen receptor (CAR) natural killer (NK) cell therapy was reported to produce a rapid response without the adverse effects seen with conventional CAR T-cell therapies. Anti-CD19 CAR T-cell therapy, which previously received FDA approvals, has shown substantial clinical activity in B-cell cancers. However, CAR T cells can cause significant adverse effects, and manufacturing the cells is complex. NK (natural killer) cells modified to express an anti-CD19 CAR have the potential to overcome these limitations. Below is an illustration showing how NK cells originate from a blood stem cell, a hematopoietic stem cell, and the other blood / immune system cells that are their siblings.

t lymphocyte cell differentiation

AntiCD19 CAR-NK Therapy Study Details

In the study at the University of Texas MD Anderson Cancer Center, patients with relapsed (recurrent) or refractory (treatment-resistant) non-Hodgkin lymphoma (6 patients) or chronic lymphocytic leukemia (CLL, 5 patients), a total of 11 patients, received cord blood-derived, HLA-mismatched (from other people) anti-CD19 CAR-NK cells. NK cells were transduced with a retroviral vector expressing genes encoding anti-CD19 CAR, interleukin-15, and inducible caspase 9 as a safety switch (in other words, modified to bind to cancer cells). Modified NK cells were generated and expanded. Low-dose chemotherapy was given beforehand to make room for the new cells in the bone marrow, and the cells were administered intravenously as a single dose.

what are lymphoid cancers which types are there

The 11 patients receiving this treatment had previously received a median of 4 different lines of therapy. All CLL patients had experienced progression after ibrutinib plus at least three other treatments. Four lymphoma patients had disease progression after autologous hematopoietic stem cell transplantation.

Study Efficacy Results

Of 11 patients, 8 (% 73) had an objective response. Among the eight responders, lymphoma completely regressed in four and CLL in three. Responses were observed within 30 days of infusion at all dose levels. CAR-NK cells continued to proliferate steadily in the body after administration and could persist at low levels for ≥ 12 months. Below is a simple summary of the mechanism of action of anti-CD19 CAR-NK therapy.

car nk cell mechanism of action

Study Safety Results

The maximum tolerated dose was not reached. No cases of cytokine release syndrome, neurotoxicity, or graft-versus-host disease were observed, and inflammatory cytokine levels, including interleukin-6, did not increase from baseline. Ten patients had grade 3 or 4 (severe) lymphopenia and neutropenia. No grade 3 or 4 nonhematological adverse effects or tumor lysis syndrome occurred. Four patients had grade 1 or 2 tachycardia (palpitations), and one patient had grade 3 electrolyte abnormalities. In conclusion, relapsed or refractory CD19-positive cancers in 11 patients: most responded to CAR-NK cell treatment without developing major adverse effects.

Sources

Enli Liu ve ark.
Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors.
NEJM 6 Feb 2020

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

A New Living Cancer Drug for Treating Lymphoid Tumors: CAR-NK

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy